作者
Heribert Schunkert, Andreas Boening, Moritz Von Scheidt, Clarissa Lanig, Friederike Gusmini, Antoinette de Waha, Constantin Kuna, Andreas Fach, Christina Grothusen, Martin Oberhoffer, Christoph Knosalla, Thomas Walther, Bernhard C Danner, Martin Misfeld, Uwe Zeymer, Gerhard Wimmer-Greinecker, Matthias Siepe, Herko Grubitzsch, Alexander Joost, Andreas Schaefer, Lenard Conradi, Jochen Cremer, Christian Hamm, Ruediger Lange, Peter W Radke, Rainer Schulz, Guenther Laufer, Philippe Grieshaber, Philip Pader, Tim Attmann, Michael Schmoeckel, Alexander Meyer, Tibor Ziegelhoeffer, Rainer Hambrecht, Adnan Kastrati, Sigrid E Sandner
发表日期
2019/8/1
期刊
European Heart Journal
卷号
40
期号
29
页码范围
2432-2440
出版商
Oxford University Press
简介
Aims
The antiplatelet treatment strategy providing optimal balance between thrombotic and bleeding risks in patients undergoing coronary artery bypass grafting (CABG) is unclear. We prospectively compared the efficacy of ticagrelor and aspirin after CABG.
Methods and results
We randomly assigned in double-blind fashion patients scheduled for CABG to either ticagrelor 90 mg twice daily or 100 mg aspirin (1:1) once daily. The primary outcome was the composite of cardiovascular death, myocardial infarction (MI), repeat revascularization, and stroke 12 months after CABG. The main safety endpoint was based on the Bleeding Academic Research Consortium classification, defined as BARC ≥4 for periprocedural and hospital stay-related bleedings and BARC ≥3 for post-discharge bleedings. The study was prematurely halted after recruitment of 1859 out of 3850 planned …
学术搜索中的文章
H Schunkert, A Boening, M Von Scheidt, C Lanig… - European Heart Journal, 2019